engleski

Benefit of Helicobacter pylori eradication therapy in all systemic sclerosis patients regardless of clinical symptoms

The aim of the study was to investigate a possible association between H. pylori infection with clinical manifestations and severity score. Our data suggest that H. pylori infection correlates with severity of skin, gastrointestinal, and joint/tendon involvement in SSc patients even without dyspeptic symptoms. H. pylori-positive SSc patients had a higher severity and activity score compared to H. pylori-negative. Therefore, H. pylori infection may play a role in the pathogenesis of SSc and also can provide some prognostic information. In a disease as varied, complex, and rare as SSc, infection prevalence alone should not be expected to provide sufficient evidence for or against a pathologic role in the disease. Alternatively, eradication and prevention of putative infectious triggers of SSc with drug prophylaxis may provide an answer in the long term. However, careful evaluation of H. pylori infection and eradication therapy could be beneficial for SSc patients.

Helicobacter pylori, systemic sclerosis

nije evidentirano